ARMATA PHARMACEUTICALS, INC. Deferred Tax Assets, Operating Loss Carryforwards
ARMATA PHARMACEUTICALS, INC. (ARMP) had Deferred Tax Assets, Operating Loss Carryforwards of $66.90 million as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-25
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $66.90M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $53.62M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $46.59M; Deferred Tax Assets, Operating Loss Carryforwards as first filed $46.59K.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $42.52K; Deferred Tax Assets, Operating Loss Carryforwards as first filed $42.52M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards | Deferred Tax Assets, Operating Loss Carryforwards as first filed |
|---|---|---|
| 2025-12-31 | $66.90M 10-K · filed 2026-03-25 | |
| 2024-12-31 | $53.62M 10-K · filed 2026-03-25 | |
| 2023-12-31 | $46.59M 10-K · filed 2025-03-21 | $46.59K 10-K · filed 2024-03-21 |
| 2022-12-31 | $42.52K 10-K · filed 2024-03-21 | $42.52M 10-K · filed 2023-03-16 |
| 2021-12-31 | $36.41M 10-K · filed 2023-03-16 | |
| 2020-12-31 | $31.24M 10-K · filed 2022-03-17 | |
| 2019-12-31 | $26.29M 10-K · filed 2021-03-18 | |
| 2018-12-31 | $17.04M 10-K · filed 2020-03-19 | $44.16M 10-K · filed 2019-03-25 |
| 2017-12-31 | $44.05M 10-K · filed 2019-03-25 | |
| 2016-12-31 | $67.48M 10-K · filed 2018-03-14 | |
| 2015-12-31 | $65.42M 10-K · filed 2017-03-27 | |
| 2014-12-31 | $61.33M 10-K · filed 2016-03-30 | |
| 2013-12-31 | $59.05M 10-K · filed 2015-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |